The clinical success of ADCs has driven the development of B7-H3-directed ADCs, including dual-payload constructs, combining cytotoxic agents with immune activation in preclinical models of triple negative breast cancer, indicating a combined therapeutic strategy targeting both tumor cells and the immunosuppressive microenvironment [235]. The gene discussed is CD276; the disease is triple-negative breast carcinoma.